Literature DB >> 27371

Haemodynamic and tolerance studies in man of a new, orally active, selective beta1-adrenoceptor agonist H 80/62.

G Johnsson, L Jordö, P Lundborg, O Rönn, I Welin-Fogelberg, J Wikstrand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 27371     DOI： 10.1007/BF00609978

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  THE EFFECT OF DESLANOSIDE ON THE DURATION OF THE PHASES OF VENTRICULAR SYSTOLE IN MAN.

Authors:  A M WEISSLER; A R KAMEN; R S BORNSTEIN; C D SCHOENFELD; S COHEN
Journal:  Am J Cardiol       Date:  1965-02       Impact factor: 2.778

2.  Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work.

Authors:  G Johnsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Distortion of non-invasive cardiac pulse curves. A capillary-damped pick-up and a calibration unit forapex cardiograms and other pulse curves.

Authors:  J Wikstrand; K Nilsson; I Wallentin
Journal:  Br Heart J       Date:  1977-09

4.  Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists.

Authors:  E Carlsson; C G Dahlöf; A Hedberg; H Persson; B Tångstrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

5.  Systolic time intervals as measures of the contractile state of the left ventricular myocardium in man.

Authors:  S S Ahmed; G E Levinson; C J Schwartz; P O Ettinger
Journal:  Circulation       Date:  1972-09       Impact factor: 29.690

Review 6.  Recent beta-adrenoreceptor stimulants.

Authors:  R T Brittain; D Jack; A C Ritchie
Journal:  Adv Drug Res       Date:  1970

7.  A comparison of the beta-adrenoceptor stimulant properties of salbutamol, orciprenaline and soterenol with those of isoprenaline.

Authors:  J B Farmer; G P Levy; R J Marshall
Journal:  J Pharm Pharmacol       Date:  1970-12       Impact factor: 3.765

8.  In vivo analysis of adrenergic receptor activity of dobutamine.

Authors:  N W Robie; D O Nutter; C Moody; J L McNay
Journal:  Circ Res       Date:  1974-05       Impact factor: 17.367

9.  Bedside technics for the evaluation of ventricular function in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Am J Cardiol       Date:  1969-04       Impact factor: 2.778

10.  Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.

Authors:  R R Tuttle; J Mills
Journal:  Circ Res       Date:  1975-01       Impact factor: 17.367
View more
  20 in total

1.  The lack of a pronounced preference of prenalterol for the beta-l-adrenoceptor subtype.

Authors:  N Rohm; J Wagner; H J Schümann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980       Impact factor: 3.000

2.  Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08

3.  Haemodynamic effects, plasma concentrations and tolerance of orally administered prenalterol in man.

Authors:  A Weiss; B Pfister; P Imhof; P H Degen; D Burckhardt; U C Dubach
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

4.  Haemodynamic effects of prenalterol in patients with coronary heart disease.

Authors:  I Hutton; R G Murray; R N Boyes; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1980-02

5.  Immediate central and regional haemodynamic effects of a new beta 1-adrenergic stimulating drug, xamoterol (Corwin) in healthy volunteers.

Authors:  M Tangø; J E Carlsen; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

Authors:  A C Tweddel; R G Murray; D Pearson; W Martin; I Hutton
Journal:  Br Heart J       Date:  1982-04

7.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

8.  Pharmacokinetic studies in man of the selective beta 1-adrenoceptor agonist, prenalterol.

Authors:  C Graffner; K J Hoffmann; G Johnsson; P Lundborg; O Rönn
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.

Authors:  P J Currie; M J Kelly; K Middlebrook; J Federman; E Sainsbury; J Ashley; A Pitt
Journal:  Br Heart J       Date:  1984-05

10.  Lack of effect of prenalterol on dialysis-associated hypotension.

Authors:  J Ladefoged
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.